Literature DB >> 19712128

Molecular pathology of early stage chemically induced hepatocarcinogenesis.

Katsuhiro Ogawa1.   

Abstract

In the early stage of chemically induced hepatocarcinogenesis, rare hepatocytes are transformed into preneoplastic hepatocytes, which progressively evolve into cells with increasing neoplastic phenotypes. Preneoplastic hepatocytes have gene expression different from normal hepatocytes, presumably from the outset. Some of these gene products are related to the growth and survival of the preneoplastic hepatocytes themselves, while others seem to involve the interaction of preneoplastic hepatocytes with non-parenchymal cell components (paracrine mechanism). Carcinogen treatment, in contrast, usually causes chronic liver injury and continuous liver regeneration, which causes selective expansion of neoplastic hepatocytes due to the fact that the neoplastic hepatocytes are resistant to cellular stress, while proliferation of normal hepatocytes is suppressed by this stress. The formation of neoplastic lesions seems to create a new microenvironment within/around the lesions, which in turn may isolate the preneoplastic hepatocytes from the normal hepatic tissues, further favoring the survival and proliferation of the preneoplastic hepatocytes. Transformation of normal hepatocytes into preneoplastic hepatocytes, their selection for growth and their isolation from the normal hepatic environment are therefore considered the fundamental principles for hepatocarcinogenesis, and this unique gene expression in preneoplastic hepatocytes together with changes in the affected liver are thought to be related to these phenomena.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19712128     DOI: 10.1111/j.1440-1827.2009.02416.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  7 in total

1.  Unique Properties of Hepatocarcinogenesis-Resistant DRH Rat Hepatocytes Linked or Not Linked to the Drh1 Locus on Rat Chromosome 1.

Authors:  Norikazu Hashimoto; Masahiro Yamamoto; Masaaki Miyakoshi; Hiroki Tanaka; Katsuhiro Ogawa
Journal:  Int J Hepatol       Date:  2011-07-25

2.  Osteopontin enhances the expression and activity of MMP-2 via the SDF-1/CXCR4 axis in hepatocellular carcinoma cell lines.

Authors:  Rihua Zhang; Xiaolin Pan; Zuhu Huang; Georg F Weber; Guoxin Zhang
Journal:  PLoS One       Date:  2011-08-31       Impact factor: 3.240

3.  4-Methylthio-3-butenyl isothiocyanate (raphasatin) exerts chemopreventive effects against esophageal carcinogenesis in rats.

Authors:  Isamu Suzuki; Young-Man Cho; Tadashi Hirata; Takeshi Toyoda; Jun-Ichi Akagi; Yasushi Nakamura; Eun Young Park; Azusa Sasaki; Takako Nakamura; Shigehisa Okamoto; Koji Shirota; Noboru Suetome; Akiyoshi Nishikawa; Kumiko Ogawa
Journal:  J Toxicol Pathol       Date:  2016-07-04       Impact factor: 1.628

4.  Diethylnitrosamine Increases Proliferation in Early Stages of Hepatic Carcinogenesis in Insulin-Treated Type 1 Diabetic Mice.

Authors:  A S Arboatti; F Lambertucci; M G Sedlmeier; G Pisani; J Monti; M de L Álvarez; D E A Francés; M T Ronco; C E Carnovale
Journal:  Biomed Res Int       Date:  2018-04-23       Impact factor: 3.411

5.  Detection of hepatocarcinogens by combination of liver micronucleus assay and histopathological examination in 2-week or 4-week repeated dose studies.

Authors:  Shuichi Hamada; Miyuki Shigano; Yumi Wako; Kazufumi Kawasako; Kensuke Satomoto; Tatsuya Mitsumoto; Takayuki Fukuda; Wakako Ohyama; Takeshi Morita; Makoto Hayashi
Journal:  Genes Environ       Date:  2022-01-04

6.  MRI contrast enhancement of liver pre-neoplasia using iron-tannic nanoparticles.

Authors:  Thipjutha Phatruengdet; Jannarong Intakhad; Monreudee Tapunya; Arpamas Chariyakornkul; Chi Be Hlaing; Rawiwan Wongpoomchai; Chalermchai Pilapong
Journal:  RSC Adv       Date:  2020-09-24       Impact factor: 3.361

7.  Metformin inhibits early stage diethylnitrosamine‑induced hepatocarcinogenesis in rats.

Authors:  Woori Jo; Eun-Sil Yu; Minsun Chang; Hyun-Kyu Park; Hyun-Ji Choi; Jae-Eun Ryu; Sungwoong Jang; Hyo-Ju Lee; Ja-June Jang; Woo-Chan Son
Journal:  Mol Med Rep       Date:  2015-11-06       Impact factor: 2.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.